Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Evolus receives conditional FDA acceptance of Jeuveau brand name [Seeking Alpha]

Evolus, Inc. (EOLS) 
Last evolus, inc. earnings: 2/25 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: us.evolis.com/investor-relations
Company Research Source: Seeking Alpha
FDA conditionally accepts Evolus' (NASDAQ: EOLS ) Jeuveau brand name for its lead product candidate DWP-450 (prabotulinumtoxinA) and its premier partnership with The American Society for Aesthetic Plastic Surgery (ASAPS). Final approval is conditional on the FDA approval of DWP-450. The PDUFA action date is February 2, 2019. U.S. commercial launch is anticipated in Spring 2019. Click to subscribe to real-time analytics on EOLS Now read: FDA rejects Aquestive's marketing application for tadalafil oral film » Subscribe for full text news in your inbox Show less Read more
Impact Snapshot
Event Time:
EOLS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
EOLS alerts

from News Quantified
Opt-in for
EOLS alerts

from News Quantified